How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
The Fund seeks to provide shareholders with regular income, conservation of principal and an opportunity for long-term growth of principal and income by investing in common stocks, preferred stocks, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results